These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1190719)

  • 1. [Proceedings: Plasma renin activity in management of Addison's disease (author's transl)].
    Linquette M; Lefebvre J; Fossati P; Fourlinnie JC; Cappoen JP; Lecieux P
    Ann Endocrinol (Paris); 1975; 36(2):103-4. PubMed ID: 1190719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement.
    Oelkers W; L'age M
    Klin Wochenschr; 1976 Jul; 54(13):607-12. PubMed ID: 940296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
    Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fludrocortisone withdrawal on plasma angiotensin II, ACTH, vasopressin, and potassium in patients with Addison's disease.
    Oelkers W; Bähr V
    Acta Endocrinol (Copenh); 1987 Jul; 115(3):325-30. PubMed ID: 3039766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin, angiotensin, corticosteroids, and electrolyte balance in Addison's disease.
    Brown JJ; Fraser R; Lever AF; Robertson JI; James VH; McCusker J; Wynn V
    Q J Med; 1968 Jan; 37(145):97-118. PubMed ID: 4297956
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment.
    Letizia C; Cerci S; Centanni M; De Toma G; Subioli S; Scuro L; Scavo D
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):145-8. PubMed ID: 9579224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acutely raised corticotropin levels in Addison's disease are not associated with increased plasma arginine vasopressin and corticotropin-releasing factor concentrations in peripheral plasma.
    Wittert GA; Livesey JH; Florkowski C; Or HK; Donald RA; Espiner EA
    J Clin Endocrinol Metab; 1993 Jan; 76(1):192-6. PubMed ID: 8380605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid replacement in Addison's disease.
    Thompson DG; Mason AS; Goodwin FJ
    Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Orthostatic hypotension in complicated diabetes mellitus: study of the renin-angiotensin-aldosterone system (author's transl)].
    Lefebvre J; Blacker C; Fossati P; Linquette M
    Diabete Metab; 1979 Mar; 5(1):11-5. PubMed ID: 446829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture.
    Wong PY; Talamo RC; Williams GH; Colman RW
    J Clin Invest; 1975 Apr; 55(4):691-8. PubMed ID: 235559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Laboratory monitoring of therapy in Addison's disease].
    Kreze A; Kreze-Spirová E; Putz Z
    Vnitr Lek; 1996 Sep; 42(9):627-31. PubMed ID: 8984771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that patients with Addison's disease are undertreated with fludrocortisone.
    Smith SJ; MacGregor GA; Markandu ND; Bayliss J; Banks RA; Prentice MG; Dorrington-Ward P; Wise P
    Lancet; 1984 Jan; 1(8367):11-4. PubMed ID: 6140341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hypertension and heart failure in patients with Addison's disease.
    Inder WJ; Meyer C; Hunt PJ
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):789-92. PubMed ID: 25138826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.
    Oelkers W; Diederich S; Bähr V
    J Clin Endocrinol Metab; 1992 Jul; 75(1):259-64. PubMed ID: 1320051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in patients with treated Addison's disease.
    Braatvedt GD; Joyce M; Evans M; Clearwater J; Reid IR
    Osteoporos Int; 1999; 10(6):435-40. PubMed ID: 10663342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High plasma levels of endothelin-1 in untreated Addison's disease.
    Letizia C; Centanni M; Scuro L; Canettieri G; Cerci S; De Ciocchis A; D'Ambrosio C; Scavo D
    Eur J Endocrinol; 1996 Dec; 135(6):696-9. PubMed ID: 9025715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [How should the plasma ACTH level in treated Addison's disease patients be interpreted?].
    Pehuet-Figoni M; Bertagna X; Girard F; Bricaire H; Luton JP
    Ann Endocrinol (Paris); 1989; 50(1):54-7. PubMed ID: 2543260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sodium restriction and prostaglandin inhibition on the renin-angiotensin system in man.
    Speckart P; Zia P; Zipser R; Horton R
    J Clin Endocrinol Metab; 1977 May; 44(5):832-7. PubMed ID: 870512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density is reduced in female but not male subjects with Addison's disease.
    Florkowski CM; Holmes SJ; Elliot JR; Donald RA; Espiner EA
    N Z Med J; 1994 Feb; 107(972):52-3. PubMed ID: 8115069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease].
    Heureux F; Maiter D; Boutsen Y; Devogelaer JP; Jamart J; Donckier J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):179-83. PubMed ID: 10970940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.